SVRA - サバラ (Savara Inc.)

SVRAのニュース

   Savara Provides Pipeline and Business Update  2020/12/10 13:05:00 Business Wire
AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today provided an update on changes to the Company’s pipeline, leadership, and business operations that are being taken to improve alignment of resources and increase our focus on Molgradex in aPAP and the Phase 3 IMPALA 2 trial. “I am grateful for the opportunity to be a part of the Savara team,” said Matt Pauls, Chairman and CEO, Savara. “Over the last few months, we have moved decisively and with urge
   Savara Announces Participation in Fireside Chats at Two Upcoming Virtual Investor Healthcare Conferences  2020/11/24 21:15:00 Business Wire
AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that Savara Management will participate in virtual fireside chats at the following investor healthcare conferences: Piper Sandler Annual Healthcare Conference: The recorded fireside chat will be available to registered attendees on the Piper Sandler Conference website from today through December 3, 2020. A replay of the event will be available on the Investors page of Savara’s website at
   Savara (NASDAQ:SVRA) & ZIOPHARM Oncology (NASDAQ:ZIOP) Critical Review  2020/11/19 19:27:40 Transcript Daily
Savara (NASDAQ:SVRA) and ZIOPHARM Oncology (NASDAQ:ZIOP) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, risk, dividends, institutional ownership, profitability, valuation and analyst recommendations. Profitability This table compares Savara and ZIOPHARM Oncology’s net margins, return on equity and return on […]
   Savara to Present at the Jefferies Virtual London Healthcare Conference  2020/11/11 21:05:00 Business Wire
AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that Matthew Pauls, Chairman and Interim CEO, will be presenting at the Jefferies Virtual London Healthcare Conference on Wednesday, November 18, 2020 at 2:55 PM EST/11:55 AM PST. Interested parties can access a live audio webcast on the Investors page of the Savara website at www.savarapharma.com/investors/events-presentations/. Please connect to the Company's website at least 15 minutes
   Savara Reports Third Quarter 2020 Financial Results and Provides Business Update  2020/11/05 21:20:00 Business Wire
AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today reported financial results for the third quarter ending September 30, 2020 and provided a business update. “After recently joining the management team, it’s clear that we must focus on three priorities in the near-term,” said Matthew Pauls, Chairman and Interim CEO, Savara. “The first is advancing our lead program, Molgradex in aPAP and the Phase 3 IMPALA 2 trial, as quickly and as safely as we can
   Savara Announces Participation in Fireside Chats at Two Upcoming Virtual Investor Healthcare Conferences  2020/11/24 21:15:00 Business Wire
AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that Savara Management will participate in virtual fireside chats at the following investor healthcare conferences: Piper Sandler Annual Healthcare Conference: The recorded fireside chat will be available to registered attendees on the Piper Sandler Conference website from today through December 3, 2020. A replay of the event will be available on the Investors page of Savara’s website at
   Savara (NASDAQ:SVRA) & ZIOPHARM Oncology (NASDAQ:ZIOP) Critical Review  2020/11/19 19:27:40 Transcript Daily
Savara (NASDAQ:SVRA) and ZIOPHARM Oncology (NASDAQ:ZIOP) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, risk, dividends, institutional ownership, profitability, valuation and analyst recommendations. Profitability This table compares Savara and ZIOPHARM Oncology’s net margins, return on equity and return on […]
   Savara to Present at the Jefferies Virtual London Healthcare Conference  2020/11/11 21:05:00 Business Wire
AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that Matthew Pauls, Chairman and Interim CEO, will be presenting at the Jefferies Virtual London Healthcare Conference on Wednesday, November 18, 2020 at 2:55 PM EST/11:55 AM PST. Interested parties can access a live audio webcast on the Investors page of the Savara website at www.savarapharma.com/investors/events-presentations/. Please connect to the Company's website at least 15 minutes
   Savara Reports Third Quarter 2020 Financial Results and Provides Business Update  2020/11/05 21:20:00 Business Wire
AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today reported financial results for the third quarter ending September 30, 2020 and provided a business update. “After recently joining the management team, it’s clear that we must focus on three priorities in the near-term,” said Matthew Pauls, Chairman and Interim CEO, Savara. “The first is advancing our lead program, Molgradex in aPAP and the Phase 3 IMPALA 2 trial, as quickly and as safely as we can
   Savara Inc (NASDAQ:SVRA) Expected to Post Earnings of -$0.20 Per Share  2020/10/24 11:41:01 Zolmax News
Wall Street analysts expect Savara Inc (NASDAQ:SVRA) to post earnings per share (EPS) of ($0.20) for the current fiscal quarter, Zacks reports. Zero analysts have made estimates for Savara’s earnings. Savara reported earnings of ($0.30) per share during the same quarter last year, which indicates a positive year-over-year growth rate of 33.3%. The company is […]
   Savara Announces Senior Management Changes  2020/09/11 12:05:00 Business Wire
AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that Rob Neville has resigned as the Company’s Chief Executive Officer (CEO) and from the Board of Directors, effective immediately, to pursue other opportunities. The Company’s Board of Directors has appointed Matthew Pauls as Chairman and Interim CEO. Mr. Pauls has served as a member of Savara’s Board of Directors since 2017 and is a seasoned biopharmaceutical leader with extensive expe
   Savara to Present at the 22nd Annual H.C. Wainwright Annual Investment Conference Being Held Virtually  2020/09/09 20:05:00 Business Wire
AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that Savara management will be presenting at the H.C. Wainwright Annual Investment Conference on Wednesday, September 16, 2020 at 3:00 PM EDT/12:00 PM PDT. Interested parties can access a live audio webcast on the Investors page of the Savara website at www.savarapharma.com/investors/events-presentations/. Please connect to the Company's website at least 15 minutes prior to the start of t
   Savara Announces New England Journal of Medicine (NEJM) Publication of IMPALA Study Results  2020/09/08 12:05:00 Business Wire
AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that results from the Phase 3 IMPALA study were published online in NEJM. The manuscript, titled “Inhaled Molgramostim Therapy in Autoimmune Pulmonary Alveolar Proteinosis,” appears in the September 7, 2020 online version of the publication and can be found at www.nejm.org. The IMPALA study evaluated molgramostim nebulizer solution (an inhaled granulocyte-macrophage colony-stimulating fac
   The Daily Biotech Pulse: AbbVie In-licenses I-Mab's Cancer Drug, Savara Pulls The Plug On Cystic Fibrosis Study  2020/09/04 11:28:02 Benzinga
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 3) Akouos Inc (NASDAQ: AKUS ) FibroGen Inc (NASDAQ: FGEN )(reacted to an adverse clinical readout for a rival drug to treat chronic kidney disease related anemia) Generation Bio Co (NASDAQ: GBIO ) Immunovant Inc (NASDAQ: IMVT ) Sutro Biopharma Inc (NASDAQ: STRO ) ( reacted to announcement concerning presentation of positive data for ovarian cancer drug) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Sept. 3) Akebia Therapeutics Inc (NASDAQ: AKBA ) (announced negative safety results for a late-stage study of drug to treat chronic kidney disease-induced anemia) AnPac Bio-Medical Science Co Ltd – ADR (NASDAQ: ANPC ) Cyclacel Pharmaceuticals Inc (NASDAQ: CYCC ) Eyepoint Pharmaceuticals Inc (NASDAQ: EYPT ) Genfit SA (NASDAQ: GNFT ) Gritstone Oncology Inc (NASDAQ: GRTS ) Happiness Biotech Group Ltd (NASDAQ: HAPP ) Homology Medicines Inc (NASDAQ: FIXX ) Immatics NV (NASDAQ: IMTX ) Interpace Biosciences Inc (NASDAQ: IDXG ) Jaguar Health Inc (NASDAQ: JAGX ) Legend Biotech Corp (NASDAQ: LEGN ) Monopar Therapeutics Inc (NASDAQ: MNPR ) NanoVibronix Inc (NASDAQ: NAOV ) Odonate Therapeutics Inc (NASDAQ: ODT ) RA Medical Systems Inc (NYSE: RMED ) Recro Pharma Inc (NASDAQ: REPH ) Rockwell Medical Inc (NASDAQ: RMTI ) Soliton Inc (NASDAQ: SOLY ) Sun BioPharma, Inc. (NASDAQ: SNBP ) Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS ) Teligent Inc (NASDAQ: TLGT ) Related Link: Attention Biotech Investors: Mark Your Calendar For September PDUFA Dates Stocks In Focus Lilly Gets FDA Nod For 2 Higher Doses of Its Best-selling Diabetes Drug Eli Lilly And Co (NYSE: LLY ) said the FDA approved two additional doses of its Type 2 diabetes drug Trulicity.
   Savara to Present at the 40th Annual Canaccord Genuity Global Growth Conference to be Held Virtually  2020/08/05 12:05:00 Business Wire
AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that the Company's Chief Executive Officer, Rob Neville, will present at the virtual Canaccord Genuity Global Growth Conference on Wednesday, August 12, 2020 at 8:00 a.m. Eastern Time / 5:00 a.m. Pacific Time. Interested parties can access a live audio webcast on the Investors page of the Savara website at www.savarapharma.com/investors/events-presentations/. Please connect to the Company

calendar